# PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

> **NCT07028424** · PHASE2 · NOT_YET_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 206 (estimated)

## Conditions studied

- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Nal-IRI
- **DRUG:** Ciprofloxacin
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-Fluorouracil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07028424
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2029-07
- **Final completion:** 2030-12
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028424, "PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07028424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*